Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L606 in Pulmonary Hypertension Associated With Interstitial Lung Disease
NCT07285655Phase 3Recruiting
- Sponsor
- Liquidia Corporation
- Start
- Apr 2026
- Primary completion
- Jul 2029
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 12
01
Overview
A Phase 3 trial of L606 in pulmonary hypertension (PH), sponsored by Liquidia Corporation. Started Apr 2026; status: recruiting.
02
Drugs
L606
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07285655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285655.